Fritz C. Eilber, MD

Fritz C. Eilber, MD

Professor, Department of Surgery
Professor, Department of Molecular and Medical Pharmacology
Director, UCLA JCCC Sarcoma Program


English, Spanish


Sarcoma Surgery, Surgical Oncology

Institutional Affiliation

Ronald Reagan UCLA Medical Center



Surgical Oncology, Memorial Sloan-Kettering Cancer Center, 2002 - 2004


General Surgery, UCLA School of Medicine, 1995 - 1996


MD, UCLA School of Medicine, 1995


General Surgery, UCLA School of Medicine, 1996 - 2002

Board Certification

Surgery, American Board of Surgery, 2003

Clinical Interests


Scientific Interests

Dr. Fritz Eilber's research is focused on translating molecular oncology from the laboratory to the clinic in a rapid and clinically relevant manner with the goal of swiftly impacting patient care. His objective is to rationally apply molecularly targeted therapies and individualized therapeutic strategies for patients with sarcoma.

Highlighted Publications

Russell TA, Eckardt MD, Murakami T, Elliott IA, Kawaguchi K, Kiyuna T, Igarashi K, Li Y, Crompton JG, Graham DS, Dry SM, Bernthal NM, Yanagawa J, Kalbasi A, Federman NC, Chmielowski B, Singh AS, Hoffman RM, Eilber FC. Clinical Factors Impacting the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): A UCLA Sarcoma Program Prospective Clinical Trial. JCO Precision Oncology, August 4, 2017.

Murakami T, Kiyuna T, Kawaguchi K, Igarashi K, Singh AS, Hiroshima Y, Zhang Y, Zhao M, Miyake K, Nelson SD, Dry SM, Li Y, DeLong JC, Lwin TM, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle. 2017 Jun 3;16(11):1046-1052. doi: 10.1080/15384101.2017.1304340. Epub 2017 Mar 15.

Shurell E, Singh AS, Crompton JG, Jensen S, Li Y, Dry S, Nelson S, Chmielowski B, Bernthal N, Federman N, Tumeh P, Eilber FC. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Oncotarget. 2016 Sep 27;7(39):64300-64308. doi: 10.18632/oncotarget.11734.

Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James AW, Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, Hiroshima Y, Russell T, Eckardt MA, Yanagawa J, Federman N, Matsuyama R, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget. 2016 Jul 26;7(30):47556-47564. doi: 10.18632/oncotarget.9879.

Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honore C, Lev DC, Colombo C, Bonvalot S, Mariani L, Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013 May 1;31(13):1649-55. doi: 10.1200/JCO.2012.44.3747. Epub 2013 Mar 25.